Relative contribution of VKORC1, CYP2C9, and INR response to warfarin stable dose

被引：15
作者：
Suarez-Kurtz, Guilherme [1 ]
Perini, Jamila A. [1 ]
Silva-Assuncao, Edimilson [1 ]
Struchiner, Claudio J. [1 ]
机构：
[1] Inst Nacl Canc, Div Farmacol, BR-21230050 Rio De Janeiro, Brazil
来源：
BLOOD | 2009年 / 113卷 / 17期
关键词：
POLYMORPHISMS; REQUIREMENTS;
D O I：
10.1182/blood-2009-01-200600
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4125 / 4126
页数：2
相关论文
共 50 条
  • [21] The VKORC1 and CYP2C9 genotypes are associated with over-anticoagulation during initiation of warfarin therapy in children
    Biss, T. T.
    Avery, P. J.
    Williams, M. D.
    Brandao, L. R.
    Grainger, J. D.
    Kamali, F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 (02) : 373 - 375
  • [22] A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose
    Takeuchi, Fumihiko
    McGinnis, Ralph
    Bourgeois, Stephane
    Barnes, Chris
    Eriksson, Niclas
    Soranzo, Nicole
    Whittaker, Pamela
    Ranganath, Venkatesh
    Kumanduri, Vasudev
    McLaren, William
    Holm, Lennart
    Lindh, Jonatan
    Rane, Anders
    Wadelius, Mia
    Deloukas, Panos
    PLOS GENETICS, 2009, 5 (03):
  • [23] Extremely low warfarin dose in patients with genotypes of CYP2C9*3/*3 and VKORC1-1639A/A
    Gao Lei
    He Lei
    Luo Jin
    Xu Bin
    Yang Jie
    Zhang Yu-xiao
    Yang Ting
    Li Ke
    Tian Jin-wen
    Wang Hong-juan
    Zhao Yu-sheng
    Lu Cai-yi
    Zhang Wen-zi
    Yin Tong
    CHINESE MEDICAL JOURNAL, 2011, 124 (17) : 2767 - 2770
  • [24] The Bleeding Risk during Warfarin Therapy Is Associated with the Number of Variant Alleles of CYP2C9 and VKORC1 Genes
    Tomek, Ales
    Mat'oska, Vaclav
    Kolarova, Tereza
    Neumann, Jiri
    Sramek, Martin
    Sarbochova, Ivana
    Taborsky, Ludek
    Bojar, Martin
    Goetz, Petr
    Serebruany, Victor L.
    CARDIOLOGY, 2013, 125 (03) : 182 - 191
  • [25] Effect of CYP2C9 and VKORC1 genetic polymorphisms on mean daily maintenance dose of acenocoumarol in South Indian patients
    Kumar, Dhakchinamoorthi Krishna
    Madhan, Sivalingam
    Balachander, Jayaramen
    Chandran, B. V. Sai
    Thamijarassy, Bascarne
    Adithan, Chandrasekaran
    THROMBOSIS RESEARCH, 2013, 131 (04) : 363 - 367
  • [26] Effect of CYP2C9 and VKORC1 Gene Variants on Warfarin Response in Patients with Continuous-Flow Left Ventricular Assist Devices
    Topkara, Veli K.
    Knotts, Robert J.
    Jennings, Douglas L.
    Garan, A. Reshad
    Levin, Allison P.
    Breskin, Alexander
    Castagna, Francesco
    Cagliostro, Barbara
    Yuzefpolskaya, Melana
    Takeda, Koji
    Takayama, Hiro
    Uriel, Nir
    Mancini, Donna M.
    Eisenberger, Andrew
    Naka, Yoshifumi
    Colombo, Paolo C.
    Jorde, Ulrich P.
    ASAIO JOURNAL, 2016, 62 (05) : 558 - 564
  • [27] Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population
    Kumar, Dhakchinamoorthi Krishna
    Shewade, Deepak Gopal
    Loriot, Marie-Anne
    Beaune, Philippe
    Balachander, Jayaraman
    Chandran, B. V. Sai
    Adithan, Chandrasekaran
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 70 (01) : 47 - 56
  • [28] CYP2C9, CYP4F2, VKORC1 Gene Polymorphism in Buryat Population
    Sambyalova, A. Yu.
    Bairova, T. A.
    Belyaeva, E. V.
    Ershova, O. A.
    Sargaeva, D. S.
    Kolesnikov, S. I.
    RUSSIAN JOURNAL OF GENETICS, 2020, 56 (12) : 1496 - 1503
  • [29] Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population
    Mitchell, Cathrine
    Gregersen, Nerine
    Krause, Amanda
    PHARMACOGENOMICS, 2011, 12 (07) : 953 - 963
  • [30] Frequencies of polymorphisms in CYP2C9 and VKORC1 genes influencing warfarin metabolism in Slovak population: implication for clinical practice
    Krajciova, L.
    Deziova, L.
    Petrovic, R.
    Luha, J.
    Turcani, P.
    Chandoga, J.
    BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2014, 115 (09): : 563 - 568
12345